Selected article for: "antiviral drug development and host target"
Author: Li, Cui-Cui; Wang, Xiao-Jia; Wang, Hwa-Chain Robert
Title: Repurposing host-based therapeutics to control coronavirus and influenza virus
  • Cord-id: r4snyxr9
  • Document date: 2019_1_31
    • ID: r4snyxr9
    Snippet: The development of highly effective antiviral agents has been a major objective in virology and pharmaceutics. Drug repositioning has emerged as a cost-effective and time-efficient alternative approach to traditional drug discovery and development. This new shift focuses on the repurposing of clinically approved drugs and promising preclinical drug candidates for the therapeutic development of host-based antiviral agents to control diseases caused by coronavirus and influenza virus. Host-based a
    Document: The development of highly effective antiviral agents has been a major objective in virology and pharmaceutics. Drug repositioning has emerged as a cost-effective and time-efficient alternative approach to traditional drug discovery and development. This new shift focuses on the repurposing of clinically approved drugs and promising preclinical drug candidates for the therapeutic development of host-based antiviral agents to control diseases caused by coronavirus and influenza virus. Host-based antiviral agents target host cellular machineries essential for viral infections or innate immune responses to interfere with viral pathogenesis. This review discusses current knowledge, prospective applications and challenges in the repurposing of clinically approved and preclinically studied drugs for newly indicated antiviral therapeutics.

    Search related documents:
    Co phrase search for related documents
    • abl abelson and acute sars cov respiratory syndrome coronavirus: 1, 2
    • acid phenethyl ester and acute sars cov respiratory syndrome coronavirus: 1, 2
    • activity interfere and acute sars cov respiratory syndrome coronavirus: 1, 2, 3, 4
    • acute sars cov respiratory syndrome coronavirus and adaptive immune system: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23
    • acute sars cov respiratory syndrome coronavirus and adaptive immune system activate: 1
    • acute sars cov respiratory syndrome coronavirus and additional application: 1, 2
    • acute sars cov respiratory syndrome coronavirus and additional effect: 1, 2
    • acute sars cov respiratory syndrome coronavirus and additional molecular target: 1
    • acute sars cov respiratory syndrome coronavirus and adenocarcinoma cell: 1, 2, 3
    • acute sars cov respiratory syndrome coronavirus and administration route: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
    • adaptive immune system and administration route: 1
    • additional application and administration route: 1